GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Haohai Biological Technology Co Ltd (HKSE:06826) » Definitions » ROC (Joel Greenblatt) %

Shanghai Haohai Biological Technology Co (HKSE:06826) ROC (Joel Greenblatt) % : 24.15% (As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Shanghai Haohai Biological Technology Co ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Shanghai Haohai Biological Technology Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 24.15%.

The historical rank and industry rank for Shanghai Haohai Biological Technology Co's ROC (Joel Greenblatt) % or its related term are showing as below:

HKSE:06826' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 13.27   Med: 47.08   Max: 78.59
Current: 26.78

During the past 10 years, Shanghai Haohai Biological Technology Co's highest ROC (Joel Greenblatt) % was 78.59%. The lowest was 13.27%. And the median was 47.08%.

HKSE:06826's ROC (Joel Greenblatt) % is ranked better than
90.12% of 1467 companies
in the Biotechnology industry
Industry Median: -333.95 vs HKSE:06826: 26.78

Shanghai Haohai Biological Technology Co's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -18.00% per year.


Shanghai Haohai Biological Technology Co ROC (Joel Greenblatt) % Historical Data

The historical data trend for Shanghai Haohai Biological Technology Co's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Haohai Biological Technology Co ROC (Joel Greenblatt) % Chart

Shanghai Haohai Biological Technology Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 37.28 20.01 26.27 13.27 26.00

Shanghai Haohai Biological Technology Co Quarterly Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 24.24 28.21 28.55 25.01 24.15

Competitive Comparison of Shanghai Haohai Biological Technology Co's ROC (Joel Greenblatt) %

For the Biotechnology subindustry, Shanghai Haohai Biological Technology Co's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shanghai Haohai Biological Technology Co's ROC (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shanghai Haohai Biological Technology Co's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Shanghai Haohai Biological Technology Co's ROC (Joel Greenblatt) % falls into.



Shanghai Haohai Biological Technology Co ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(358.607 + 575.518 + 124.118) - (351.978 + 0 + 194.174)
=512.091

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(357.13 + 579.696 + 138.12) - (418.857 + 0 + 319.573)
=336.516

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Shanghai Haohai Biological Technology Co for the quarter that ended in Mar. 2024 can be restated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=507.672/( ( (1698.685 + max(512.091, 0)) + (1657.363 + max(336.516, 0)) )/ 2 )
=507.672/( ( 2210.776 + 1993.879 )/ 2 )
=507.672/2102.3275
=24.15 %

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shanghai Haohai Biological Technology Co  (HKSE:06826) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Shanghai Haohai Biological Technology Co ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Shanghai Haohai Biological Technology Co's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Shanghai Haohai Biological Technology Co (HKSE:06826) Business Description

Traded in Other Exchanges
Address
No. 1386 Hongqiao Road, 23rd Floor, WenGuang Plaza, Changning District, Shanghai, CHN
Shanghai Haohai Biological Technology Co Ltd is engaged in the manufacturing and sale of biologicals, medical hyaluronate, and ophthalmology products. It is also engaged in the research and development of biological engineering, pharmaceutical and ophthalmology products, and the provision of related services. Its products are categorized into four types comprising ophthalmology, medical aesthetics, orthopedics, and anti-adhesion. Geographically, it has operations in Mainland China which is the key revenue driver, the United States, the United Kingdom, and other countries.

Shanghai Haohai Biological Technology Co (HKSE:06826) Headlines

No Headlines